LogicBio Therapeutics
LogicBio Therapeutics was a clinical-stage genetic medicine company developing gene therapy and genome editing treatments for rare genetic diseases, acquired by Alexion (AstraZeneca Rare Disease) in 2022.
- Company typePublic
- Founded2015
- HeadquartersFoster City, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What LogicBio Therapeutics does
LogicBio Therapeutics was a clinical-stage genetic medicine company founded in 2014 and headquartered in Lexington, Massachusetts. The company developed gene therapy and genome editing treatments targeting rare genetic diseases, with a pipeline focused on monogenic disorders including methylmalonic acidemia (MMA) and hemophilia B. It served patients with rare inherited conditions that lacked adequate treatment options, positioning itself within the orphan disease segment of the gene therapy market.
The company's core technology centered on proprietary platforms including the GeneRide genome editing platform (a homologous recombination-based approach for in vivo gene integration) and the sAAVy capsid technology for tissue-targeted AAV delivery. These platforms formed the technical foundation of the company's pipeline and represented its primary intellectual property assets. LogicBio operated with 51-100 employees and maintained research collaborations with academic institutions in the gene therapy field, including its founding institutions. The company went public on NASDAQ under ticker LOGC in 2018 to fund clinical advancement of its pipeline.
LogicBio's business model was that of a pre-commercial clinical-stage biotech. The company generated revenue primarily through collaboration and license agreements rather than product sales, consistent with the $43 million in reported revenue that likely represents one-time license or milestone payments. With a net loss of $29 million, the company's economics reflected the heavy R&D investment typical of clinical-stage gene therapy developers. In 2022, LogicBio was acquired by Alexion Pharmaceuticals (now part of AstraZeneca Rare Disease), and it now operates as a subsidiary contributing gene therapy and genome editing capabilities to AstraZeneca's rare disease portfolio.
LogicBio Therapeutics firmographics
Firmographics- Name
- LogicBio Therapeutics
- Legal name
- LogicBio Therapeutics
- Website
- https://logicbio.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- LogicBio Therapeutics was a clinical-stage genetic medicine company developing gene therapy and genome editing treatments for rare genetic diseases, acquired by Alexion (AstraZeneca Rare Disease) in 2022.
- Ownership category
- akta.pro rank
LogicBio Therapeutics industry classification
Industry- Product category
- Gene Therapy & Genome Editing Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)
- akta.pro secondary industries
- AAV Vector Gene Therapy Developers (HLAAACAA), Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo) (HLAAACAD)
Keywords
Where LogicBio Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Foster City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
LogicBio Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Gene therapy product revenue: LogicBio Therapeutics generated revenue through the development and commercialization of gene therapy treatments for genetic diseases.
LogicBio Therapeutics product offering
Product offeringCore offering
LogicBio Therapeutics developed gene therapy vectors and genome editing treatments targeting rare genetic and infectious diseases. The company leveraged proprietary AAV-based delivery technology to create therapies for previously incurable inherited conditions, operating as a clinical-stage genetic medicine company prior to its 2022 acquisition by Alexion.
Product overview
LogicBio Therapeutics was a genetic medicine company that developed genome editing and gene therapy treatments for genetic diseases. The company operated from Lexington, Massachusetts. In 2022, LogicBio was acquired by Alexion (AstraZeneca Rare Disease). The company had approximately $43 million in revenue and was developing treatments in the gene therapy space. Fred Chereau served as President and CEO of LogicBio prior to the acquisition.
Differentiator
Problem solved
Functional benefit
Products and services
- Gene Therapy Treatments LogicBio Therapeutics developed gene therapy treatments for patients with rare genetic diseases, leveraging proprietary genome editing and AAV-based delivery technology to address previously incurable inherited conditions.
- Genome Editing Technologies LogicBio Therapeutics' proprietary genome editing technologies formed a core component of the company's genetic medicine platform for treating rare genetic diseases, including genome editing approaches such as those for rare inherited disorders.
Companies that use LogicBio Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
LogicBio Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
LogicBio Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AlexioncoreLogicBio Therapeutics was acquired by Alexion in 2022. This acquisition brought LogicBio's gene therapy capabilities under Alexion's rare disease portfolio, with former LogicBio CEO Fred Chereau transitioning to Senior Vice President at Alexion - AstraZeneca Rare Disease and subsequently to CEO of Sensorion.
Scale indicators4 records
Recent moves6 records
Expansion highlights3 records
LogicBio Therapeutics competitors and assessment
Company assessmentDirect peers
- CRISPR Therapeutics: Pioneer in CRISPR/Cas9 genome editing therapeutics for rare genetic diseases including sickle cell disease and beta thalassemia. Directly comparable gene editing platform approach with overlapping indications.
- bluebird bio: Direct competitor developing gene therapies and genome editing approaches for rare genetic diseases, including hemoglobinopathies and neurological conditions. Highly comparable in modality, indication focus, and target patient population.
- uniQure: Gene therapy company focused on AAV-based treatments for rare diseases, including CNS and metabolic disorders. Directly comparable platform approach targeting monogenic conditions with high unmet need.
- Editas Medicine: Genome editing company developing CRISPR-based and engineered Cas9 therapies for rare genetic diseases including inherited retinal disorders. Comparable genome editing modality and rare disease focus.
- Regenxbio: AAV gene therapy platform company developing treatments for rare diseases including retinal, metabolic, and neuromuscular conditions. Comparable AAV vector technology and rare disease focus.
Broad incumbents
- Sarepta Therapeutics: Established gene therapy player with approved products for Duchenne muscular dystrophy. Broader incumbent with commercial rare disease gene therapy portfolio and significant revenue.
- Spark Therapeutics (Roche): Acquired by Roche, Spark is a gene therapy pioneer (Luxturna) focused on rare inherited diseases. Larger platform with approved products, making it a broad incumbent in the rare disease gene therapy space.
Emerging players
- Passage Bio: Clinical-stage AAV gene therapy company targeting rare CNS disorders. Comparable platform approach with similar stage of development and rare monogenic disease focus.
- GenSight Biologics: Gene therapy company developing AAV-based treatments for rare ophthalmologic and CNS diseases. Comparable modality (AAV gene therapy) and rare disease positioning.
- Taysha Gene Therapies: Clinical-stage gene therapy company developing AAV-based treatments for rare CNS diseases. Comparable platform, similar rare disease focus, and overlapping patient populations.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
LogicBio Therapeutics social profiles
Digital presenceLogicBio Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
LogicBio Therapeutics leadership team
Management profileNumber of profiles
LogicBio Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LogicBio Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LogicBio Therapeutics
What does LogicBio Therapeutics do?
LogicBio Therapeutics developed gene therapy vectors and genome editing treatments targeting rare genetic and infectious diseases. The company leveraged proprietary AAV-based delivery technology to create therapies for previously incurable inherited conditions, operating as a clinical-stage genetic medicine company prior to its 2022 acquisition by Alexion.
Is LogicBio Therapeutics a public or private company?
LogicBio Therapeutics is a public company. It is classified as corporate owned and is currently acquired.
When was LogicBio Therapeutics founded?
LogicBio Therapeutics was founded in 2015. It employs 51 to 100 people.
Where is LogicBio Therapeutics based?
LogicBio Therapeutics is headquartered in Foster City, United States, in the North America region.
How does LogicBio Therapeutics make money?
One revenue line is on record: gene therapy product revenue.
Who are LogicBio Therapeutics's main competitors?
Direct peers on record are CRISPR Therapeutics, bluebird bio, uniQure, Editas Medicine and Regenxbio. Broad incumbents are Sarepta Therapeutics and Spark Therapeutics (Roche). Emerging players are Passage Bio, GenSight Biologics and Taysha Gene Therapies.
Does LogicBio Therapeutics have an API?
No public API is recorded for LogicBio Therapeutics.
What industry is LogicBio Therapeutics in?
LogicBio Therapeutics's product category is Gene Therapy & Genome Editing Therapeutics. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2836.